CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABA_A receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses anticonvulsant activity but may negatively impact cognitive performance. However, barbiturates are still commonly abused, leading to tolerance and physical dependence over time. Abrupt cessation can result in withdrawal symptoms, including seizures, which calls for a gradual dose reduction and potential replacement with the use of non-benzodiazepine anti-anxiety treatments like buspirone.

Benzodiazepines, like midazolam, diazepam, and lorazepam, also act on GABA receptors to provide inhibitory effects, with risks of respiratory depression when administered intravenously. Despite their reduced prescription rate, barbiturates are sold illegally on the streets. Benzodiazepine abuse usually occurs concurrently with opioids. Abusers of high doses often require inpatient detoxification using long-acting benzodiazepines or barbiturates to manage withdrawal symptoms effectively. After detoxification, long-term outpatient rehabilitation is necessary to prevent relapse, but specific medications for sedative abusers' rehabilitation remain elusive. Physicians should exercise caution when prescribing barbiturate hypnotics, and long-term use of sedative medications should be avoided to prevent disruptions in normal sleep physiology and worsened insomnia upon cessation. Lastly, it's crucial to discourage the use of alcohol to relieve insomnia, as it may exacerbate sleep quality issues.